Exxel Pharma, INC.

FWP supplemental

Price $5.00 · Range $4.00 to $6.00 · 2,500,000 shares · Gross proceeds $10,000,000

Exxel Pharma, Inc. is advancing its lead candidate, EX937, a small molecule targeting refractory chronic cough and potential expansion into high-value indications like neuropathic pain and migraine. The company is preparing for its initial public offering (IPO) with an estimated share price range of $4.00 to $6.00, offering 2,500,000 to 3,750,000 shares. The filing highlights progress in clinical development, including Phase 1/1b studies, and outlines the use of proceeds for drug development, regulatory activities, and corporate purposes.

FWP supplemental

Price $4.00 · Range $4.00 to $6.00 · 3,000,000 shares · Gross proceeds $12,000,000

Exxel Pharma, Inc. is conducting an IPO to advance its lead candidate EX937, a small-molecule FAAH inhibitor for refractory chronic cough and other neuronal hypersensitivity disorders. The offering aims to raise $15 million, with proceeds allocated to clinical trials, drug development, and operational expenses. The company highlights EX937's peripheral mechanism, avoiding CNS side effects, and targets Phase 1/1b trials in 2026. The filing emphasizes a $11 billion market opportunity for chronic cough and potential expansion into neuropathic pain and migraine indications.

S-1/A amended

Exxel Pharma, Inc. is conducting an IPO to raise capital for the development of its lead product candidate, EX937, a small-molecule FAAH inhibitor targeting refractory chronic cough (RCC) and other hypersensitivity disorders. The company aims to list on the NYSE American under the symbol 'EXXL' and plans Phase I/Ib clinical trials in 2026. The filing includes underwriting details, with Joseph Gunnar & Co., LLC as the lead underwriter, and highlights the speculative nature of the investment.

S-1/A amended

Price $5.00 · 476,149 shares

Exxel Pharma, Inc. is a biopharmaceutical company focused on developing EX937, a novel small-molecule FAAH inhibitor, for refractory chronic cough (RCC) and other hypersensitivity disorders. The company plans to conduct a Phase I/Ib clinical trial in 2026, pending capitalization and manufacturing, and aims to list shares on OTCQX or OTCQB. The S-1/A amendment covers the resale of 476,149 shares by selling shareholders, with no proceeds to the company. The filing highlights EX937's unique CNS exclusion, preclinical data, and potential market opportunities, while emphasizing risks related to clinical trials, regulatory approvals, and market competition.

S-1 filed

476,149 shares

Exxel Pharma, Inc. is a biopharmaceutical company developing EX937, a novel small-molecule inhibitor of fatty acid amide hydrolase (FAAH), for treating neuronal hypersensitivity disorders such as refractory chronic cough (RCC). The company is preparing for its initial public offering (IPO) to fund Phase I clinical trials, with plans to list on the OTCQX or OTCQB markets. EX937 is designed to avoid the central nervous system, reducing side effects, and has potential for expansion into hyperactive bladder, neuropathic pain, and migraine. The filing highlights preclinical data, patent protection through 2031-2044, and reliance on a single product candidate.